A combined viral capsid antigen and Epstein-Barr nuclear antigen1 (VCA/EBNA1) immunoglobulin A (IgA) antibody score has been developed that uses a logistic regression model (logit P = -3.934 + 2.203 x IgA anti-VCA + 4.797 x IgA anti-EBNA) to predict NPC and was formally evaluated in a large cluster randomized trial in the Guangdong Province (NCT-00941538). This evidence concerns the gene CD79A and nasopharyngeal carcinoma.